Minisola and colleagues [1] comment that two randomized control trials (RCTs) (Sanders et al. [2] and Smith et al. [3] ) lack important information concerning the distribution of risk factors for falls (cognitive impairment, drug use, alcohol use, etc.) in the two arms. Sanders et al. reported that at baseline the prevalence of risk factors for falls and fractures as well as previous fractures since the age of 50 years were similar in the vitamin D and placebo groups. Smith et al. [4] reported that previous fractures were similar in the two groups. Since more than 90 % of fractures occur after a fall, it is highly unlikely that a difference in baseline prevalence of risk factors for falls existed in either study. Furthermore, participants in both studies were randomized only if mentally competent to participate. Similar scores of mental well-being parameters and the use of antidepressants at baseline have been reported in the vitamin D and placebo groups in another Sanders et al. study [5] .
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Most importantly, both trials had over 2,000 participants, so random allocation would ensure that any common characteristic, such as falls in subjects in their late 70s, would be evenly distributed. This is a fundamental characteristic that ranks the RCT as the highest level of clinical evidence, only outranked by meta-analysis of multiple RCTs.
Minisola et al. [1] suggest that if it is fluctuation in serum 25(OH)D, rather than the peak value reached, that is associated with increased falls/fracture risk and that the problem might be overcome by using intramuscular injection, which causes a slower increase in plasma 25(OH)D than oral administration. We do not disagree that fluctuation may be the problem, but the fact that similar adverse effects on older women were seen in both RCTs, despite the different routes of administration, suggests that the cause is more complex than simply the route of administration or the rate of rise of 25D.
In both studies, 25(OH)D levels 3-4 months postdose were only modestly (approximately 20 %) elevated above predose levels. In the Smith et al. [3] study the very small number assayed (n = 30 treated, 13 placebo) reduced the power to detect a significant difference in 25(OH)D at 4 months. However, there was a greater (35.7 %) increase in 1,25-dihydroxyvitamin D, which was significant (P \ 0.002).
Minisola and colleagues [1] confirm the urgent need for RCTs with physical outcomes as primary end points. A study design that adheres to the CONSORT guidelines and is appropriately randomized and adequately powered would be balanced in risk factors for falls and fractures between treatment and placebo groups.
We agree that Grant [6] has identified common limitations of prospective cohort studies. Our article states that we did not attempt to present a ''balanced'' view of a potential risk/benefit ratio of vitamin D supplementation but summarized results from studies using intermittent, high doses of vitamin D, with particular attention to those finding evidence of adverse effects.
Grant [6] states the limitation that in many prospective studies serum 25(OH)D was measured at the time of enrollment with long follow-up periods for cancer outcomes. We agree that vitamin D status taken years prior to the diagnosis may be irrelevant; but these population-based studies are hypothesis-generating, and the associations need to be tested using the gold-standard randomized placebo-controlled study design. Grant also correctly points out the potential flaws of case-control studies where vitamin D status is compared between groups with and without the disease. The cases may have taken measures to improve their vitamin D status as a consequence of the diagnosis.
We would welcome the conduct of ''properly designed'' vitamin D RCTs. However, Grant's guidelines for such are speculative and raise additional questions. (1) Determining the ''concentration-health outcome relation'' would rely on high-quality, well-controlled data that are not available. Furthermore, any such data derived from observational studies will be problematic because the relation may be quite different in an interventional study when the concentrations are dynamic. (2) The rate and magnitude of the increase in serum 25(OH)D levels may be critical. (3) Due to individual variation, a set dose may not achieve a concentration ''near the upper end''-many will be well above or below this. Therefore, the dose will need to be titrated in each participant, causing issues with blinding and logistics. (4) At which time points after dosing should the concentrations be measured? (5) Finally, in the very large, longterm studies required to determine clinical end points, the cost of performing multiple biochemical assays is a major impediment.
